0001193125-26-094013
SEC filingREGENXBIO Inc. reported total revenues of $170.4 million for FY 2025, a significant increase from $83.3 million in FY 2024, driven by a $74.3 million increase in license and royalty revenue primarily from a $72.9 million up-front license fee under the Nippon Shinyaku collaboration and a $1.7 million increase in Zolgensma/Itvisma royalties. Despite revenue growth, the company incurred a net loss of $193.9 million, an improvement from a $227.1 million loss in FY 2024, as increased operating expenses ($331.6 million vs. $316.7 million) and higher interest expense ($45.0 million vs. $12.7 million) were partially offset by revenue gains. The company ended the year with $240.9 million in cash, cash equivalents, and marketable securities, which management estimates will fund operations into early 2027, though substantial doubt exists about its ability to continue as a going concern beyond that point without additional capital or successful product commercialization.
REGENXBIO reported FY 2025 total revenues of $170.4 million, a 104% increase from $83.3 million in FY 2024. This growth was driven by a $74.3 million increase in license and royalty revenue to $156.3 million, primarily from a $72.9 million up-front license fee recognized under the Nippon Shinyaku collaboration and a $1.7 million increase in Zolgensma and Itvisma royalties to $83.2 million. Service revenue increased by $12.8 million to $14.2 million, largely from RGX-121 development services. Despite revenue growth, the company reported a net loss of $193.9 million, an improvement from a $227.1 million loss in FY 2024. Operating expenses increased to $331.6 million from $316.7 million, while interest expense surged to $45.0 million from $12.7 million due to royalty monetization liabilities.
Revenue growth was concentrated in two areas: license/royalty revenue and service revenue. License and royalty revenue of $156.3 million included $72.9 million from the Nippon Shinyaku up-front payment and $83.2 million from Zolgensma and Itvisma royalties, based on Novartis sales of $1.23 billion in 2025 ($1.21 billion in 2024). Zolgensma royalties were $82.5 million and Itvisma royalties were $0.6 million following its Q4 2025 launch. Service revenue of $14.2 million primarily came from RGX-121 development and manufacturing services for Nippon Shinyaku. The company's revenues remain dependent on licensing agreements and lack product sales from its own pipeline.
Gross margin improved significantly to 88.1% in FY 2025 from 59.7% in FY 2024, as cost of license and royalty revenues decreased by $13.3 million to $20.3 million due to reduced upstream Zolgensma royalties in certain territories. Research and development expenses increased by $19.8 million to $228.3 million, driven by manufacturing costs for ABBV-RGX-314, RGX-202, and RGX-121 ($8.1 million increase), personnel costs ($5.8 million increase), and clinical trial expenses ($5.7 million increase). General and administrative expenses increased by $6.2 million to $82.9 million, primarily from professional services. The company recorded no credit losses or recoveries in FY 2025, compared to a $5.0 million recovery in FY 2024.
Net cash used in operating activities was $124.0 million in FY 2025, improved from $173.1 million in FY 2024, largely due to the $110.0 million Nippon Shinyaku up-front payment. Cash flows from investing activities used $15.9 million primarily for marketable debt security purchases. Financing activities provided $116.8 million, mainly from $144.5 million in proceeds from the 2025 Royalty Bond issuance, offset by $28.1 million in royalty monetization liability repayments. The company ended FY 2025 with $240.9 million in cash, cash equivalents, and marketable securities, total assets of $453.0 million, total liabilities of $350.3 million (including $187.0 million in royalty monetization liabilities), and stockholders' equity of $102.7 million.
Management estimates that current cash, cash equivalents, and marketable securities of $240.9 million will fund operations into early 2027, but substantial doubt exists about the company's ability to continue as a going concern beyond that point without additional capital or successful product commercialization. Key near-term catalysts include topline data from ABBV-RGX-314 pivotal trials in Q4 2026, RGX-202 topline data in early Q2 2026, and ongoing discussions with the FDA regarding the RGX-121 CRL and clinical hold. The company plans to use the Leerink ATM Program (up to $150.0 million) for general corporate purposes and continues to depend on achieving development milestones under collaborations with AbbVie and Nippon Shinyaku for future funding.